Navigation Links
Pharmos Corporation Completes Initial Closing of Private Placement
Date:1/3/2008

ISELIN, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial closing the Company issued $4,000,000 principal amount of the Debentures, at par, and received gross proceeds in the same amount.

The purchasers consisted of certain existing investors in the Company, namely Venrock Associates, New Enterprise Associates, Lloyd I. Miller, III and Robert Johnston.

The Debentures mature the earlier of November 1, 2012 or the sale of the Company. The Debentures, together with all accrued and unpaid interest thereon, may be repaid, without premium or penalty, commencing on November 1, 2011.

Starting on November 1, 2009 (or earlier sale of the Company), any outstanding Debenture may be converted at the option of the holder. The conversion price is fixed equal to $0.70 per share.

The Debentures bear interest at the rate of 10% per annum, payable semi-annually either in cash or common stock of the Company at the option of the Company.

Under the terms of the offering, the Company may raise gross proceeds up to an aggregate of $8,000,000 from the sale of Debentures in the placement (including the Debentures issued at the initial closing). A second closing is targeted for no later than 45 days from the date of the initial closing.

The proceeds will be used for working capital, in particular for the ongoing Phase 2b trial for dextofisopam.

The securities issued and issuable in the offering have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or applicable
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmos Corporation Announces Board and Management Changes
2. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Reports 2007 Third Quarter Results
5. Pharmos Issues Letter to Shareholders
6. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
7. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
8. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
9. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Nearly 20,000 medical professionals ... Annual Meeting & Clinical Lab Expo in ... never-before-seen breakthroughs in diagnostic research and technology that will ... As of Wednesday, July 30, more than ... Meeting & Clinical Lab Expo, with more than 10,000 ...
(Date:7/31/2014)... Researchers at Johns Hopkins have mapped the sound-processing part ... both the proverbial forest and the trees in view. ... views of brain activity within mice, and it enabled ... mice "called" to each other. The results, which represent ... process language, appear online July 31 the journal ...
(Date:7/31/2014)... PORTOLA VALLEY, Calif. , July 31, 2014 /PRNewswire/ ... San Francisco Bay Area , has ... the University of Oxford,s commercialisation company. The potent anti-inflammatory ... David Greaves at the University of Oxford,s Sir ... The company, which has raised over $1.5 million ...
(Date:7/31/2014)... Research and Markets has announced ... report to their offering. ... of the genetic material or genomes of an organism. ... the discovery and development of diagnostic and therapeutic solutions ... Genomics is supported by three major product segments: Instruments, ...
Breaking Biology Technology:Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 2Research on Digital Health, Alzheimer's, Ebola Draws Nearly 20,000 Attendees to 2014 AACC Annual Meeting & Clinical Lab Expo 3New mapping approach lets scientists zoom in and out as the brain processes sound 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... the appointment of James Stoppert as President and Chief Executive Officer ... ... EON) September 3, 2008 -- Segetis is the first and ... wide range of industrial chemicals and plastics that are ultimately derived ...
... China, Sept. 3 ,Acesys Pharmatech and Provid Pharmaceuticals ... expertise and project management,capabilities of Provid in the ... structure of Acesys in China., The combined ... of medicinal chemistry for clients in the pharmaceutical ...
... tested new molecular tools for stem cell research to direct ... development programmes. , A collaborative team of scientists from ... (NESCI) have developed two synthetic molecules which can be used ... into other forms of tissue. , Their use ...
Cached Biology Technology: Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc 2Acesys and Provid Announce Alliance for Medicinal Chemistry Services 2New stem cell tools to aid drug development 2New stem cell tools to aid drug development 3
(Date:7/31/2014)... , July 31, 2014 Biometrics ... and innovative smart technologies; companies turn towards digital currency: ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ), ... (NASDAQ: GOOG ) and Microsoft Corporation (NASDAQ: ... focused on the growing m-commerce market, announces a video ...
(Date:7/31/2014)... nuts (almonds, Brazil nuts, cashews, hazelnuts, macadamias, pecans, pine ... online publications, British Medical Journal Open (BMJ Open) ... BMJ Open article looked at the effects ... showed that tree nut consumption resulted in a significant ... PLOS ONE article focused on the effect of ...
(Date:7/30/2014)... Inspired by the Red Queen in Lewis Carroll,s ... of Illinois and National University of Singapore improved ... species evolve over decades to millions of years. ... model for competition, incorporates the "Red Queen Effect," ... in the 1970s, which suggests that organisms must ...
Breaking Biology News(10 mins):Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 2Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 3Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 4Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 5Smart Technology Consumer's Interest in Mobile Payment Products Grows - Company Secures Deal with Major Airline to Display Advertisements in Flight for its Next Generation Smart Wallet 6New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... G&D, Dr. Guillermo Oliver (St. Jude Childrens ... resolve a century-old debate over the origin of ... the lymphatic vasculature is integral to understanding its ... tissue fluid levels) and disease (lymphedema and spreading ...
... of the scientific journal Science presents research on the ... that ultimately may lead to better diagnosis and treatment ... people every year. It may also bring an ... Giardia lamblia is an intestinal parasite that exists all ...
... Standards and Technology (NIST) today announced 56 ... development projects under the agencys Advanced Technology ... a broad range of technologies, including medical ... electronics, transportation, nanotechnology, energy conservation and automated ...
Cached Biology News:New Swedish research hope for millions of sufferers 2
... for ambient HPLC. Contains connections and ... two external devices such as RI ... analog output from the 90 detector ... Includes an input for synchronization with ...
... The FDSS6000 System is an imaging ... assay development and high throughput screening ... luminescence modalities., The Hamamatsu light sources ... our companys decades-long experience in photon ...
... and supplies, for 10 chips, provides ... perform standard-sensitivity RNA analysis (nanogram levels) ... automated electrophoresis system. Supplied are 1,250 ... StdSens stain, 20 microliters RNA ladder, ...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. PROTECT FROM ... cell-permeable sulfanamido-benzbromarone compound that acts as ... inhibitor of PTP1B (IC 50 ... for PTP1B 403 and PTP1B ...
Biology Products: